Archive · 18 Sep 2025
Lupin Receives US FDA Nod for Cancer Drug
Lupin, a drug company, got permission from the US government to sell a cancer medicine called Lenalidomide Capsules.
This medicine is similar to another one already sold.
The medicine will be made in Lupin's factory and will treat adults with different types of cancer, including multiple myeloma.
This drug has the potential to generate $7.5 billion in sales annually in the US.
However, Lupin's stock price slightly decreased.
Lupin received USFDA approval for Lenalidomide Capsules.
The drug is a generic version of Bristol-Myers Squibb's Revlimid.
Lenalidomide Capsules are for treating adult cancer patients.
The product will be manufactured at Lupin’s Pithampur facility.
Lupin's shares were trading down after the news.
- Who
- Lupin
- What
- Received USFDA approval to market Lenalidomide Capsules.
- When
- Wednesday (mentioned in the article)
- Where
- US market, manufactured at the Pithampur facility.
- Why
- To market the generic cancer treatment drug in the US market.
Lupin
Bristol-Myers Squibb
Market Share
Lupin
Lupin will gain market share with the new drug.
Bristol-Myers Squibb
Bristol-Myers Squibb might see a decline in sales of Revlimid.
- Company
- Lupin
- Drug
- Lenalidomide Capsules
- USFDA Approval
- Received
- Indication
- Cancer Treatment
- Equivalent to
- Bristol-Myers Squibb Company’s Revlimid
- Annual Sales (US)
- $7,511 million
- Stock Impact
- Shares down 1.09%
